Assisted intelligence for intensive care

Intensive care is the most data-rich environment in any hospital, and with high volumes of high-fidelity clinical data it is an impeccable location to apply AI. With AlgoDx’s technology, we enable early detection of patient deterioration by augmenting healthcare provider clinical decision-making.

Our products

In a data-rich environment such as the intensive care unit, some signs of patient deterioration can be difficult to spot in time. Our product portfolio includes machine learning algorithms intended to assist clinical decision making in intensive care. Developed for conditions with high unmet medical need, these algorithms are designed to generate robust clinical evidence for product claims, covering clinical and health-economic benefits as well as potential risks.

AlgoDx intensive care proprietary pipeline as of September 2022

                              
Pre-clinical
R&D
 
Regulatory clearance
EU
 
Clinical validation
in intensive care
 
Post-marketing clinical follow-up
 
NAVOY® for sepsis prediction
                                                    
Algorithm for prediction of Acute Kidney Injury
 
                                                                           
Undisclosed Therapeutic Indication                                      
Ongoing
Complete

           

Clinical trials – AlgoDx sponsored clinical research

For more information on our ongoing clinical projects in intensive care, visit clinicaltrials.gov

ExPRESS

Early Prediction of Sepsis in Hospitalized Patients Using a Machine Learning Algorithm, a Randomized Clinical Validation Trial.

Protocol number: NCT04570618

GENIUS

Integration and Evaluation of a Machine Learning Algorithm for Sepsis Prediction in an Electronic Health Record System a Prospective Observational Study.

Protocol number: NCT05095220

AKI-SE-02

Clinical validation of an algorithm for prediction of Acute Kidney Injury in ICU patients.

Protocol number: NCT05424874

 

AlgoDx products in the clinical workflow – case study: NAVOY®